Singapore Full Evaluation Route: When It Applies and What It Costs

1. Key takeaways

When a device holds no approval from an HSA-recognised Reference Agency, or the intended use approved by the Reference Agency differs from the use proposed for Singapore, or the Reference Agency has classified it as Class I / Class II exempt, the Full evaluation route becomes mandatory. The official evaluation timelines of the Full route are: Class B 160 working days, Class C 220 working days, Class D 310 working days; the evaluation fees are 3,900 / 6,250 / 12,000 SGD respectively, plus the SGD 560 application fee.

• Full is the baseline route and the most expensive one, yet it is the only route that does not depend on overseas approvals, making it unavoidable for first-time exporters and newer products.
• The published timelines are working-day evaluation clocks that stop while HSA waits for responses to queries, so query rounds must be scheduled as a separate axis rather than treated as a buffer.
• Unlike Abridged and Expedited, the Full route offers no summary-submission facility, so the clinical evaluation under GN-20 R2 is a hard investment.
• Priority Review can compress Full-route timelines substantially, for example Class D from 310 to 202 working days, at a clearly stated extra fee.
• The real cost lever is sequencing: obtaining a Reference Agency approval before entering Singapore can halve the Class D fee and cut 90 working days.

2. Legal basis

The Full route conditions are defined in GN-15 sections 4 to 6, the dossier format follows the ASEAN CSDT structure set out in GN-17 R5 and GN-18 R5, and clinical evaluation requirements follow GN-20 R2. The fee and timeline figures below come from the official HSA fees and processing times page, updated to 26 March 2026.

3. Expert insights

Insight one: Full is the baseline route and also the most expensive route, but it is the only route that does not depend on overseas approvals.

For Chinese manufacturers entering overseas markets for the first time, for newer products, or where the Reference Agency approval does not cover the target use, Full is the necessary path. There is nothing wrong with it, but it demands precise budgeting and scheduling, because every extra query round extends the calendar without adding any fee visibility. Companies should therefore treat the Full route not as a fallback to be improvised but as a project to be planned with the same rigour as any product development milestone, with owners, deadlines and evidence readiness defined before the dossier is even assembled.

Insight two: the evaluation clock stops while waiting for responses, which is the greatest uncertainty of the Full route.

The 160/220/310 figures published by HSA are working-day evaluation clocks, and the time the applicant takes to answer queries is not counted. Our experience on Class D Full projects is to list the query rounds multiplied by the response time per round as a separate scheduling axis, not as a buffer cushion. The quality of the technical dossier directly determines the length of that axis.

Insight three: the Full route has no summary-submission facility.

Abridged and Expedited allow the preclinical and clinical chapters to be submitted in summary form; the Full route requires complete evidence. This means that the clinical evaluation (GN-20 R2) is a hard investment on the Full route, and this is especially evident for Class C/D. The full-evidence requirement is precisely why the Full route takes longer and costs more: HSA reviews the data itself rather than relying on another agency’s conclusions, so every chapter must stand on its own when the dossier arrives.

Insight four: Priority Review is an acceleration option of the Full route, but the price is explicit.

Class B Full at 160 working days can be compressed to 104 working days (Priority Route 1: SGD 4,420; Route 2: SGD 5,660). Class C Full 220 goes to 143 working days (SGD 7,000 / 9,000). Class D Full 310 goes to 202 working days (SGD 13,600 / 17,500). Whether it is worth it depends on the commercial value of the launch window (see Article 16).

Insight five: the real lever for cost reduction is moving earlier.

For the same Class D device, Abridged costs SGD 6,250 against Full at SGD 12,000. Obtaining one Reference Agency approval first (for example EU or FDA) before going to Singapore halves the fee and shortens the timeline by 90 working days. When we plan global filing sequences for clients, we usually recommend placing Singapore after the Reference Agency approval rather than before it, unless the launch window does not allow.

4. Practical recommendations

• Schedule Full-route projects on two axes, evaluation plus responses: do not count response time as a buffer.
• Get the technical dossier right the first time: first-round quality determines the number of query rounds and is the biggest cost-reduction point of the Full route.
• Assess the feasibility of obtaining the Reference Agency approval before entering Singapore: for Class D this can save SGD 5,750 plus 90 working days.
• Start the clinical evaluation early: on the Full route for Class C/D, clinical evidence is the long-cycle item.
• Treat Priority Review as a commercial decision rather than a technical one: let the commercial value of the launch window decide.

5. Verification checklist

• □ It has been confirmed that no usable Reference Agency approval exists (or the use differs, or the device is Class I / II exempt)
• □ The fee has been confirmed by class (3,900 / 6,250 / 12,000 SGD)
• □ The evaluation timeline has been confirmed by class (160 / 220 / 310 working days)
• □ Time for query responses has been scheduled separately
• □ The clinical evaluation for Class C/D has been initiated early
• □ The alternative of obtaining a Reference Agency approval first has been assessed
• □ The commercial value of Priority Review has been assessed

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com